AbbVie
ABBV
#27
Rank
NZ$794.51 B
Marketcap
NZ$449.69
Share price
0.41%
Change (1 day)
43.58%
Change (1 year)

The biotechnology and pharmaceutical company Abbvie, spelled AbbVie, was founded in 2013 as a spin-off from Abbott Laboratories and is traded on the NYSE stock exchange in the S&P 100 index under the symbol โ€œABBVโ€.

EPS for AbbVie (ABBV)

EPS in 2026 (TTM): NZ$3.51

According to AbbVie's latest financial reports the company's current EPS (TTM) is NZ$3.55. In 2025 the company made an earnings per share (EPS) of NZ$4.13 a decrease over its 2024 EPS that were of NZ$4.18.

EPS history for AbbVie from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)NZ$3.51-15%
2025NZ$4.13-1.26%
2024NZ$4.18-11.86%
2023NZ$4.75-58.95%
2022NZ$11.562.49%
2021NZ$11.28121.58%
2020NZ$5.09-44.7%
2019NZ$9.2045.84%
2018NZ$6.319.72%
2017NZ$5.75-9.54%
2016NZ$6.3616.28%
2015NZ$5.47184.1%
2014NZ$1.92-57.15%
2013NZ$4.49

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Pfizer
PFE
NZ$2.26-36.31%๐Ÿ‡บ๐Ÿ‡ธ USA
Eli Lilly
LLY
NZ$48.74 1,272.26%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
NZ$25.00 603.99%๐Ÿ‡บ๐Ÿ‡ธ USA
Biogen
BIIB
NZ$16.14 354.58%๐Ÿ‡บ๐Ÿ‡ธ USA
Gilead Sciences
GILD
NZ$12.81 260.75%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
NZ$6.15 73.08%๐Ÿ‡บ๐Ÿ‡ธ USA
AstraZeneca
AZN
NZ$12.00 237.90%๐Ÿ‡ฌ๐Ÿ‡ง UK
GSK plc
GSK
NZ$6.71 88.94%๐Ÿ‡ฌ๐Ÿ‡ง UK
Neurocrine Biosciences
NBIX
NZ$11.59 226.23%๐Ÿ‡บ๐Ÿ‡ธ USA